← FDA DRUG APPROVALS

FDA ANDA · ANDA074079

DILTIAZEM HYDROCHLORIDE

Sponsor: TEVA

APPLICATION
ANDA074079
TYPE
ANDA
ORIGINAL APPROVAL
1993-11-30
LATEST ACTION
2002-11-27
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 90MG · CAPSULE, EXTENDED RELEASE · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 60MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2002-11-27Manufacturing (CMC) · Supplement 8AP
2000-07-07Manufacturing (CMC) · Supplement 7AP
1999-03-22Manufacturing (CMC) · Supplement 6AP
1998-06-12Labeling · Supplement 5AP
1997-05-12Labeling · Supplement 4AP
1995-01-09Manufacturing (CMC) · Supplement 2AP
1994-06-30Manufacturing (CMC) · Supplement 1AP
1993-11-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →